Drug intelligence / Profile preview

CBC203

Development stage: Preclinical
Lead developer: CliPS BnC
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics

Overview

CBC203 is a recombinant protein vaccine candidate developed by CliPSBnC for the prevention of tuberculosis (TB). It is designed to elicit a protective immune response against *Mycobacterium tuberculosis*. The vaccine is currently in the preclinical stage of development. It utilizes recombinant protein technology to present specific antigens from the TB pathogen to the immune system, aiming to provide a safer and more effective alternative or supplement to the existing BCG vaccine.

Other names: CBC203 recombinant vaccineCBC-203 recombinant vaccineCBC 203 recombinant vaccine

Beyond the preview

Go deeper on CBC203.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CBC203.

Explore the full profile